Company
Invirsa
Damage control at the DNA level
Also known as INVIRSA, INC.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- INVIRSA, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Invirsa’s lead compound (INV-102), quickly and predictably augments the body’s response to DNA damage, greatly improving cell stability at the critical moment.
Funding snapshot
- Total raised
- $25.8MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed, $18.1M2025-11-03
Funding rounds
- Round, 2025
- $18.1M2025-11-03, Company stated
- Round, 2025
- $2.9M2025-07-22, SEC form D sold, 14 investors
- Round, 2023
- $1000K2023-11-14, SEC form D sold, 1 investor
- Series B
- $7.7M2023-06-14, Company stated
- Round, 2022
- $6M2022-12-21, SEC form D sold, 8 investors
- Round, 2020
- $40.2K2020-11-12, SEC form D sold, 1 investor
Products
- Other
- INV-102
Loading relationship preview